5-year Follow-Up: First-Line Nivolumab Plus Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma - Cancer Therapy Advisor
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma | British Journal of Cancer
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma | Scientific Reports
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib | SpringerLink
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma | NEJM
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Cancers | Free Full-Text | Progression-Free and Overall Survival of First- Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Frontiers | Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | BMC Cancer | Full Text
Cancers | Free Full-Text | Progression-Free and Overall Survival of First- Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
Sunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican population
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response ...
Sunitinib re-challenge in advanced renal-cell carcinoma | British Journal of Cancer
Progression-free survival (a) and overall survival (b) of patients... | Download Scientific Diagram
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - ScienceDirect
Experience with sunitinib in the treatment of metastatic renal cell carcinoma - Manuela Schmidinger, James Larkin, Alain Ravaud, 2012
